Marta O. S.
- Country
- Poland
- Department
- NA
Research Overview
Data & Insights
Has run more than one trial at 11 of 120 partner sites.
Specializations
Hormone Receptor‑Positive Breast Cancer
Investigation of advanced hormone receptor‑positive breast cancer with emphasis on endocrine‑resistant disease and biomarker‑guided therapeutic combinations.
- CDK4/6 inhibitor combinations
- PIK3CA‑mutated disease strategies
- Post‑chemotherapy maintenance approaches
- Adjuvant endocrine optimization
Integration of molecular profiling to refine patient selection for novel agents.
Non‑Small Cell Lung Cancer
Focused on targeted and immune‑based interventions for non‑small cell lung cancer, including molecularly defined subgroups.
- EGFR exon 20 insertion therapies
- KRAS‑G12C targeted agents
- PD‑L1 high disease regimens
- ALK‑positive disease management
Collaborative trials conducted through the National Oncology Institute in Warsaw.
Hematologic Malignancies
Clinical programs addressing acute leukemias and lymphoid cancers, with a strong focus on genetic drivers and cellular therapies.
- Acute myeloid leukemia with NPM1 mutation
- CAR‑T cell approaches in lymphoma
- Maintenance strategies post‑stem cell transplant
- Targeted agents in chronic lymphocytic leukemia
Application of next‑generation sequencing to personalize treatment pathways.
Gastrointestinal and Hepatobiliary Cancers
Exploration of biomarker‑driven therapies across gastrointestinal malignancies, including liver and biliary tract cancers.
- MSI‑high colorectal cancer interventions
- FGFR2b‑positive gastric cancer targeting
- KRAS‑mutated pancreatic cancer trials
- BRAF‑mutated cholangiocarcinoma approaches
Emphasis on integrating molecular diagnostics into trial eligibility.
Immunotherapy and Targeted Therapy in Solid Tumors
Broad program evaluating checkpoint inhibition and novel targets across diverse solid tumors.
- PD‑1 refractory melanoma strategies
- VEGF‑targeted renal cell carcinoma regimens
- BAP1‑deficient mesothelioma studies
- TIGIT inhibition in solid tumors
Combination designs aim to enhance response durability and overcome resistance.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.